---
title: "RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280153935.md"
description: "RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer"
datetime: "2026-03-23T11:38:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280153935.md)
  - [en](https://longbridge.com/en/news/280153935.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280153935.md)
---

# RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

### Related Stocks

- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md)
- [RemeGen Deploys Idle Cash Into RMB453 Million HTSC Wealth Products](https://longbridge.com/en/news/286484178.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)